Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Eligibility
Sex
FEMALE
Min age
45 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Inclusion Criteria:
* Female sex
* Age 45 years or older
* Postmenopausal status
* Attendance at the Physical Medicine and Rehabilitation outpatient clinic
* Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation
* Ability and willingness to provide written informed consent
Exclusion Criteria:
Exclusion Criteria:
* Premenopausal women
* Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)
* Active infection or acute inflammatory disease
* Major surgery within the previous 6 months
* Neurological or muscular disorders that may significantly affect muscle function
* Inability to comply with study procedures and assessments
* Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents
* Refusal or inability to provide written informed consent
Primary outcome measure(s)
Serum Lumican Level and Bone Mineral Density Association — Baseline (at study enrollment) Assessment of the relationship between serum lumican levels and bone mineral density (lumbar spine, total hip, and femoral neck BMD measured by DEXA).
Trial sites (1)
Facility
City
Region
Status
Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
Küçükçekmece
Istanbul
Recruiting
More Kanuni Sultan Suleyman Training and Research Hospital trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.